Introduction to Resiliva
Resiliva is identified on this website as a product containing resmetirom, with stated strengths of 80 mg and 100 mg. Resmetirom is an oral prescription medicine belonging to the selective thyroid hormone receptor-beta agonist class. It was developed for a defined group of adults with metabolic dysfunction-associated steatohepatitis (MASH), previously called nonalcoholic steatohepatitis (NASH), who have moderate to advanced liver fibrosis without cirrhosis.
This page explains the active ingredient, its recognized therapeutic role, the meaning of the stated strengths and the information patients should verify before relying on a particular product.
The specific manufacturer, marketing authorization holder, formulation and regulatory status of Resiliva have not been independently confirmed by the information available for this website. These details should be verified using authentic packaging, official product documentation and the applicable medicines regulatory authority.
Understanding Resmetirom
Resmetirom is a selective agonist of thyroid hormone receptor-beta, commonly abbreviated as THR-β. This receptor plays an important role in metabolic regulation in the liver, including pathways involved in lipid processing.
MASH is a metabolic liver disease in which excess fat in the liver is accompanied by inflammation and liver-cell injury. Continued injury can cause fibrosis, a process in which scar tissue accumulates in the liver. Advanced fibrosis increases the risk of serious liver complications.
Resmetirom is intended to improve certain measures of liver disease in appropriately selected patients. It is used alongside diet and exercise, rather than as a replacement for lifestyle management or medical supervision.
The established U.S. reference product is REZDIFFRA, developed by Madrigal Pharmaceuticals. Its approval does not automatically establish the approval, quality, manufacturing origin or interchangeability of Resiliva.
What Do the 80 mg and 100 mg Strengths Mean?
The stated strengths refer to the amount of active ingredient per dosage unit, assuming that the product’s own documentation confirms these details.
For the U.S. reference product REZDIFFRA, the labeled adult dose is based on body weight:
- Adults weighing less than 100 kg: 80 mg once daily.
- Adults weighing 100 kg or more: 100 mg once daily.
These are reference-product instructions and should not be treated as an individualized prescription for Resiliva. The applicable local prescribing information must be checked before applying any dosing guidance to another branded product.
Patients should not select a strength or change their dose without advice from a qualified healthcare professional. Body weight, other medicines, medical conditions and the relevant prescribing information may influence treatment decisions.
What Is Resiliva Intended to Treat?
The therapeutic role associated with resmetirom is the treatment of eligible adults with noncirrhotic MASH and moderate to advanced liver fibrosis. Under the U.S. reference-product indication, this corresponds to fibrosis stages F2 and F3.
MASH can develop in association with metabolic risk factors such as obesity, type 2 diabetes and abnormal blood lipid levels. However, not everyone with fatty liver disease has MASH, and not every person with MASH has the fibrosis stage for which resmetirom is indicated.
A clinician determines whether a patient meets the relevant criteria using the medical history, laboratory results, imaging, noninvasive fibrosis assessments and other investigations as appropriate.
Resmetirom should not be described as an approved treatment for every type of fatty liver disease or as a proven cure for cirrhosis.
How Resmetirom Works
Resmetirom selectively activates THR-β in the liver. This receptor is involved in metabolic pathways that regulate lipid handling and energy use.
By influencing these pathways, resmetirom can reduce liver fat and may improve measures of steatohepatitis and fibrosis in a proportion of eligible patients.
The medicine’s effects are specific to the biological pathways it targets. It does not eliminate the need to manage associated conditions such as diabetes, obesity, high cholesterol or cardiovascular risk.
Clinical improvement also varies between individuals. Patients should continue recommended follow-up appointments and investigations rather than relying on symptoms alone to determine whether treatment is working.
Safety and Tolerability
Resmetirom can cause adverse reactions and requires review of the patient’s medical history and other medicines.
Reported adverse reactions include diarrhea, nausea, itching, vomiting, constipation, abdominal discomfort and dizziness. The reference product’s prescribing information also contains a warning concerning hepatotoxicity and precautions regarding gallbladder-related adverse reactions.
Certain medicines, including some statins and drugs that affect CYP2C8, may require particular attention because of potential interactions. A healthcare professional should review all prescription medicines, nonprescription products and supplements before treatment begins.
Patients should promptly report yellowing of the skin or eyes, dark urine, persistent unusual fatigue, severe abdominal pain or other concerning symptoms. Severe or rapidly worsening symptoms require urgent medical assessment.
Product Verification
Before using Resiliva, verify the complete product name, active ingredient, dosage form, strength, manufacturer, batch number, expiry date and applicable registration details.
A familiar product name or matching strength is not sufficient evidence of authenticity or regulatory authorization. If any information is missing or inconsistent, consult a licensed pharmacist or the relevant medicines regulatory authority.
Medical Disclaimer
This page is for general educational purposes and does not replace professional medical advice or official prescribing information. Resmetirom is a prescription medicine, and eligibility for treatment must be determined by a qualified healthcare professional.
Product-specific claims about Resiliva should be supported by documentation for that exact product. Information about REZDIFFRA must not be used as proof of Resiliva’s manufacturer, approval status or formulation.
References
- U.S. Food and Drug Administration: REZDIFFRA prescribing information and approval records.
- European Medicines Agency: REZDIFFRA product information.
- Madrigal Pharmaceuticals: Official information about resmetirom and REZDIFFRA.